investors

PRESS RELEASES

Angion Initiates Dosing In Phase 1 Clinical Trial Evaluating ANG-3070, A Dual-Kinase Inhibitor For The Treatment of Fibrotic Diseases
Angion Presents Data on the Impact and Burden of Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
Angion Presents Positive Long-term Data from Phase 2 Clinical Trial of ANG-3777 in Delayed Graft Function at the American Society of Nephrology Kidney Week 2019
Angion Expands Executive Team to Support the Ongoing and Future Clinical Development of ANG-3777
see more

EVENTS

J.P. Morgan Healthcare Conference
see more

CORPORATE PRESENTATIONS

CATEGORIES